Isabella Visuri
Oerebro, T, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study.
Journal: Therapeutic advances in gastroenterology
Published: February 11, 2025
Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.
Journal: Scandinavian journal of gastroenterology
Published: October 26, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.
Journal: Therapeutic advances in gastroenterology
Published: December 12, 2022
The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study.
Journal: Inflammatory bowel diseases
Published: December 29, 2021
Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: August 23, 2021
Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG.
Journal: Scandinavian journal of gastroenterology
Published: August 20, 2021
Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
Journal: Alimentary pharmacology & therapeutics
Published: December 13, 2020
The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
Journal: Scandinavian journal of gastroenterology
Published: May 07, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026